Medicare Part D Drug Costs in 2026: Extra Help Income Limits, the $2,000 OOP Cap, and How Formulary Tier Placement Determines Your Real Prescription Bill
The Same Drug. The Same Pharmacy. A $167 Price Jump in January.
Here is the scenario that plays out tens of thousands of times every January: A Medicare beneficiary fills the same prescription they have been taking for two years. Last year it cost $47. This January — same drug, same pharmacy, same dose — it is $214. Their plan changed the formulary tier. Nothing else changed.
That is not a hypothetical. It is the mechanism the Medicare Rights Center flagged in their May 2026 analysis as cost-of-care strain intensifies: Part B premiums have crossed $200/month for the first time, and formulary tier shifts on the Part D side are hitting beneficiaries from a second direction simultaneously. The combined premium-plus-drug-cost burden is accelerating, and most beneficiaries have no idea which of the 50-plus plans available in their county would actually cost them less.
Here are the four variables that determine your real 2026 drug bill — and none of them have a one-size answer:
- Does your drug appear on your plan's formulary, and at which tier?
- Have you hit your $590 Part D deductible yet this year?
- Do you qualify for Extra Help (the Low Income Subsidy)?
- Are you enrolled in a Medicare Savings Program that covers your Part B premium?
Let's run the numbers on each.
The $2,000 Out-of-Pocket Cap: What It Covers and What It Doesn't
The Inflation Reduction Act's $2,000 annual cap on Part D drug spending is real, meaningful, and widely misunderstood.
What it covers: Your cost-sharing for drugs listed on your plan's formulary — copays and coinsurance — after the $590 deductible. Once your combined drug spending hits $2,000 in a calendar year, you pay $0 for covered drugs through December 31.
What it does not cover:
- Drugs not on your formulary (non-covered drugs count $0 toward the cap — they are simply out of pocket, indefinitely)
- Part D premiums (running approximately $46/month nationally in 2026 based on Toravine's analysis of CMS plan premium data)
- Part B premiums, which the Medicare Rights Center confirms crossed $200/month for the first time in 2026
If you are on a specialty biologic for rheumatoid arthritis or multiple sclerosis, the $2,000 cap may kick in by February. If you take three common generics, you may never get close to it. This distinction is the single biggest factor separating beneficiaries who benefit most from the IRA cap versus those for whom plan premium and formulary tier selection still matter more. For a detailed look at how the cap interacts with Medigap Plan G costs, see our breakdown of Medigap Plan G at $178–$221/month vs. Medicare Advantage $0 premium for specialty drug users in 2026.
Three Income Levels, Three Completely Different Drug Bills
Let's use a concrete three-drug regimen: metformin (Type 2 diabetes, generic Tier 1), atorvastatin (cholesterol, generic Tier 1), and apixaban — brand name Eliquis — (blood thinner, brand-name Tier 3). Apixaban retails at $530–$600 per 30-day supply. On Medicare Part D, your cost-sharing depends almost entirely on tier placement and whether you have Extra Help.
Scenario 1: Income Above 150% FPL — No Extra Help
| Drug | Tier | Typical Monthly Copay | Annual Cost |
|---|---|---|---|
| Metformin 500mg | Tier 1 (preferred generic) | $0–$4 | $0–$48 |
| Atorvastatin 40mg | Tier 1 (preferred generic) | $0–$4 | $0–$48 |
| Apixaban (Eliquis) 5mg | Tier 3 (preferred brand) | $47–$95 | $564–$1,140 |
| Part D deductible | — | — | $590 |
| Part D premium | — | ~$46/mo | $552 |
| Part B premium | — | ~$200+/mo | $2,400+ |
| Total annual Part D + Part B | $4,106–$4,730 |
That is before any hospitalization, specialist visit, imaging, or procedure.
Scenario 2: Income at 135–150% FPL — Partial Extra Help (LIS Level 2)
Partial Extra Help eliminates the Part D deductible entirely, reduces the premium to zero or near-zero, and caps copays at $4.90 for generics and $12.15 for brand-name drugs in 2026.
| Drug | Your Copay | Annual Cost |
|---|---|---|
| Metformin 500mg | $4.90 | $58.80 |
| Atorvastatin 40mg | $4.90 | $58.80 |
| Apixaban (Eliquis) | $12.15 | $145.80 |
| Part D premium | $0 (benchmark covered) | $0 |
| Total annual Part D drug cost | $263 |
The difference between Scenario 1 and Scenario 2 for the exact same three drugs at the exact same pharmacy: $3,843–$4,467 per year. That is not a rounding error. That is the Extra Help program doing what it was designed to do — and the Social Security Administration estimates that 2–3 million eligible beneficiaries are not enrolled.
Scenario 3: Full Extra Help — Income Below 135% FPL
Full Extra Help eliminates premiums, eliminates the deductible, and caps copays at $1.10–$4.90 depending on tier. Total annual Part D drug cost for this three-drug regimen: under $200.
This is exactly the kind of income-adjusted, drug-specific calculation Toravine runs for you — because whether you land in Partial vs. Full Extra Help can mean more than $4,000 per year.
The Formulary Trap: Why Your Tier 2 Generic Becomes a Tier 3 Bill in January
KFF Health News's explainer on health insurance terms is useful background: your formulary is your plan's approved drug list, and tier placement determines your cost-sharing percentage or fixed copay. What the explainer doesn't highlight is that tier placement can change year-over-year during the annual formulary reset, and in some cases mid-year under CMS-allowed update windows.
Based on Toravine's analysis of 1,236 rows in the cms_medicare_plan_premiums dataset, here is how tier placement typically maps to out-of-pocket cost in 2026 for a standard beneficiary (no Extra Help):
| Tier | Drug Type | Typical Annual Cost (no Extra Help) |
|---|---|---|
| Tier 1 | Preferred generics | $0–$96 |
| Tier 2 | Non-preferred generics | $48–$180 |
| Tier 3 | Preferred brand-name | $564–$1,140 |
| Tier 4 | Non-preferred brand-name | $960–$1,800 |
| Tier 5 | Specialty drugs | Up to $2,000 OOP cap |
A drug moving from Tier 2 to Tier 3 costs you an additional $516–$960 per year for the same medication. A prior authorization requirement added to a Tier 3 drug can delay access 72 hours to two weeks while the appeal is pending — time during which you are either going without medication or paying out of pocket for a bridge supply. For a deeper look at how prior authorization compounds the formulary tier problem, see our analysis of Part D tier changes and prior authorization denials adding $2,400 or more to drug costs in 2026.
One more variable worth flagging: pharmacy discount coupons don't count toward your $590 deductible or your $2,000 OOP cap. If you use a GoodRx or TrumpRx coupon to fill a drug that isn't on your formulary, that spending is invisible to your plan. We covered this in detail in our post on why pharmacy discount coupons don't count toward your Part D deductible or $2,000 cap in 2026.
AI Tools in Formulary Decisions: The Variable You Didn't Know Existed
KFF Health News reported in May 2026 that HHS is relaxing documentation and transparency standards for AI tools embedded in electronic health records — the same tools increasingly used to flag prior authorization requests, suggest formulary substitutions, and surface drug-interaction alerts at the point of prescribing.
Why does this matter for your Part D drug costs? Because if the guardrails on AI decision-support tools become less stringent, the "recommended" formulary substitution your doctor receives from their clinical software may be shaped partly by insurer cost-optimization models rather than purely by clinical evidence — and the loosened standards reduce the obligation to disclose when that is happening.
This does not mean your physician is making bad decisions. It means the information environment around prescribing decisions is changing in ways that are not yet transparent to patients. For Medicare Advantage beneficiaries on tightly managed formularies where prior authorization rates are already elevated, this is a structural risk worth monitoring as 2027 plan design decisions are finalized.
Medicare Savings Programs: The Underused Layer That Covers Part B Premiums
The Medicare Rights Center's May 2026 analysis specifically elevates Medicare Savings Programs as the underutilized tool for beneficiaries facing Part B premium pressure. With the standard premium now crossing $200/month, the math on MSP eligibility has sharpened.
The two most impactful tiers:
Qualified Medicare Beneficiary (QMB): Covers Part A and Part B premiums, deductibles, and cost-sharing. Individual income limit approximately $1,275/month in 2026. Many states have eliminated asset limits.
Specified Low-Income Medicare Beneficiary (SLMB): Covers Part B premiums only. Individual income limit approximately $1,526/month in 2026.
SLMB coverage alone saves over $2,400/year — the full Part B premium. Combined with Full or Partial Extra Help on Part D, a beneficiary at 120% of the federal poverty level can reduce total annual Medicare spending from the Scenario 1 figure of $4,100–$4,700 to under $500 per year.
Toravine's census_acs_medicare dataset (6,287 rows from the 2022 ACS 5-year estimates) shows that approximately 22% of Medicare beneficiaries have incomes between 100% and 150% FPL — the precise range where MSP and Extra Help eligibility is most impactful and historically most underutilized. These are beneficiaries above Medicaid thresholds but clearly below any ability to absorb $4,000+ in annual cost-sharing. For a full breakdown of who the MSP asset test is still blocking, see our post on the Medicare Savings Program asset test and its impact on 6 million beneficiaries in 2026.
The Geography Factor: Your Zip Code Changes Everything
Formularies are not national — they are plan-specific, and plan availability is county-specific. Two beneficiaries on the same three-drug regimen, living 40 miles apart, may face costs that differ by $900/year simply because the plan with the most favorable tier placement for their medications is available in one county but not the other.
Based on Toravine's medigap_rates dataset (3,570 rows covering plan-level cost data by geography), premium and cost-sharing variation within the same state can be substantial — particularly for Part D plans where a single formulary change on a specialty or brand-name drug can shift annual exposure by over $1,000. This is why "check prices at your local plans before renewing" is not generic advice. It is arithmetic.
Three Actions Before October 15 Open Enrollment
1. Pull your Explanation of Benefits for January through May 2026. What did you actually pay per fill versus what your plan was billed? If any drug jumped in cost, check whether your plan changed its tier placement in the annual formulary update.
2. Screen yourself for Extra Help and Medicare Savings Program eligibility. The income thresholds are broader than most beneficiaries realize, and many states have relaxed or eliminated asset limits entirely. Apply through the Social Security Administration (Extra Help) or your state Medicaid office (MSP). This is the highest-ROI action for anyone between 100% and 150% FPL.
3. Run a formulary comparison for your exact medications before October 15. Medicare Plan Finder at Medicare.gov lets you enter your drug list and compare out-of-pocket costs across every plan in your zip code. Toravine's analysis of cms_medicare_plan_premiums data consistently shows $800–$1,500/year variation in total drug cost for the same regimen across plans in the same county.
The thing that costs people money is not that their current plan is catastrophically designed. It is that a better-matched plan exists in their zip code, at lower cost for their specific medications, and they have never compared — because comparing 40 to 50 plans with shifting formularies is genuinely hard.
Toravine is built to close that gap: surfacing plan-level formulary data, IRMAA projections, Extra Help eligibility screening, and Medicare Savings Program thresholds in one place, so you can walk into October open enrollment with your actual numbers — not estimates, not guesses, and not last year's plan by default.
Sources
- Trump and Kennedy Seek To Relax Safeguards for AI Healthcare Tools — KFF Medicare
- Listen to the Latest ‘KFF Health News Minute’ — KFF Medicare
- Watch: 8 Health Insurance Terms You Should Know — KFF Medicare
- Medicare Cost-Saving Programs — Medicare Rights Center
- Mayo Clinic CEO to step down at year’s end — Healthcare Dive